Fujifilm Diosynth Biotechnologies

Fujifilm plant in North Carolina
Fujifilm's plant in North Carolina has been part of the COVID-19 response effort. (Fujifilm)

Fujifilm Diosynth Biotechnologies
: Novavax, Eli Lilly

Among the major contract manufacturers in the COVID-19 fight, most players have focused on chipping in on only one front—i.e. vaccines, antibodies, or generics medicines. But Fujifilm Diosynth Biotechnologies, the CDMO arm of the Japanese giant, has opted for a multiprong offensive against the novel coronavirus. 

Fueled by its specialization in novel therapy manufacturing, including monoclonal antibodies and viral vector transports, Fujifilm is working with Big Pharma Eli Lilly and biotech Novavax on COVID-19 fighting antibodies and vaccines, respectively, from its facilities in Denmark and the U.S. 

Starting back in April, Fujifilm set aside manufacturing space at its ever-growing biologics plant in Hillerød, Denmark as part of a pact with the COVID-19 Therapeutics Accelerator, a Bill Gates-backed initiative driving access to needed medicines to fight the virus. 

The agreement reserved an unspecified production volume for 2021 with options for the following years, Fujifilm said. 

RELATED: Fujifilm plots $928M infusion at Danish biologics plant to double production capacity

Fujifilm Diosynth Biotechnologies